Vanguard Group’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-4,139,600
| Closed | -$143M | – | 4255 |
|
|
2020
Q3 | $143M | Sell |
4,139,600
-62,944
| -1% | -$1.34M | ﹤0.01% | 1489 |
|
|
2020
Q2 | $70.2M | Buy |
4,202,544
+65,198
| +2% | +$1.11M | ﹤0.01% | 1837 |
|
|
2020
Q1 | $59.7M | Buy |
4,137,346
+96,511
| +2% | +$2.47M | ﹤0.01% | 1783 |
|
|
2019
Q4 | $135M | Buy |
4,040,835
+287,135
| +8% | +$8.03M | ﹤0.01% | 1602 |
|
|
2019
Q3 | $78.6M | Buy |
3,753,700
+47,306
| +1% | +$966K | ﹤0.01% | 1851 |
|
|
2019
Q2 | $77.2M | Buy |
3,706,394
+164,038
| +5% | +$3.38M | ﹤0.01% | 1887 |
|
|
2019
Q1 | $79.2M | Sell |
3,542,356
-132,718
| -4% | -$3.12M | ﹤0.01% | 1859 |
|
|
2018
Q4 | $87.9M | Buy |
3,675,074
+95,768
| +3% | +$2.48M | ﹤0.01% | 1743 |
|
|
2018
Q3 | $97.6M | Buy |
3,579,306
+135,159
| +4% | +$3.82M | ﹤0.01% | 1816 |
|
|
2018
Q2 | $92.6M | Buy |
3,444,147
+136,149
| +4% | +$4.17M | ﹤0.01% | 1820 |
|
|
2018
Q1 | $105M | Buy |
3,307,998
+721,726
| +28% | +$25.4M | ﹤0.01% | 1687 |
|
|
2017
Q4 | $97.8M | Sell |
2,586,272
-36,748
| -1% | -$1.19M | ﹤0.01% | 1738 |
|
|
2017
Q3 | $65M | Buy |
2,623,020
+146,184
| +6% | +$3.15M | ﹤0.01% | 1923 |
|
|
2017
Q2 | $50.9M | Buy |
2,476,836
+276,978
| +13% | +$5.28M | ﹤0.01% | 2009 |
|
|
2017
Q1 | $47.8M | Buy |
2,199,858
+513,803
| +30% | +$10.5M | ﹤0.01% | 2033 |
|
|
2016
Q4 | $34.5M | Buy |
1,686,055
+165,487
| +11% | +$3.38M | ﹤0.01% | 2150 |
|
|
2016
Q3 | $22.8M | Buy |
1,520,568
+180,721
| +13% | +$2.44M | ﹤0.01% | 2308 |
|
|
2016
Q2 | $14.5M | Buy |
1,339,847
+109,457
| +9% | +$1.49M | ﹤0.01% | 2470 |
|
|
2016
Q1 | $16.7M | Buy |
1,230,390
+533,582
| +77% | +$8.32M | ﹤0.01% | 2374 |
|
|
2015
Q4 | $12.9M | Buy |
696,808
+133,884
| +24% | +$2.48M | ﹤0.01% | 2497 |
|
|
2015
Q3 | $14.3M | Buy |
+562,924
| New | +$13.2M | ﹤0.01% | 2432 |
|
Vanguard Group's AIMT Position: Q4 2020 in Review
Vanguard Group sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 4,139,600 shares — an estimated $143M sold.
Vanguard Group first reported a position in AIMT in Q3 2015 and held it in 21 quarters. The position peaked at $143M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Vanguard Group reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Vanguard Group sold 4,139,600 Aimmune Therapeutics shares in Q4 2020, an estimated $143M.
- Vanguard Group first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 21 quarters.
- Vanguard Group's Aimmune Therapeutics position peaked at $143M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Vanguard Group's 13F filing for Q4 2020, filed 12 Feb 2021.